Epigenetics Regulates Antitumor Immunity in Melanoma

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• Melanoma, a malignant skin cancer, exhibits immune evasion, hindering antitumor responses.
• Immune checkpoint blockades show promise in melanoma treatment by revitalizing immune cells.
• Epigenetic dysregulation impacts melanoma cell behavior, carcinogenesis, and progression.

Purpose of the Study:

• To review melanoma epidemiology, clinical features, and therapeutic advances.
• To discuss the tumor microenvironment and immune cell roles in melanoma immunity.
• To elucidate the connection between epigenetics and antitumor immunity in melanoma.

Main Methods:

• Systematic review of existing literature on melanoma, epigenetics, and immunotherapy.
• Analysis of epigenetic mechanisms (DNA methylation, histone modification, non-coding RNAs, m6A RNA methylation) in melanoma.
• Examination of clinical trial data for epigenetics-based melanoma immunotherapy.

Main Results:

• Epigenetic dysregulation is implicated in melanoma's immune evasion and progression.
• Specific epigenetic mechanisms modulate antitumor immunity in the melanoma tumor microenvironment.
• Emerging clinical trials investigate epigenetics as a therapeutic target in melanoma immunotherapy.

Conclusions:

• Epigenetics plays a significant role in melanoma's interaction with the immune system.
• Targeting epigenetic pathways offers a promising strategy for novel melanoma immunotherapies.
• Further research into epigenetics-driven melanoma immunity is essential for clinical translation.